Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased T-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. a human subject, and related methods and uses.

Abstract: Compounds of formula (I) and salts thereof: wherein R1 is n-C1-6alkyl or C1-2alkoxyC1-2alkyl-, R2 is halo, OH or C1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.

Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.

Abstract: An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist.

Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.

Abstract: Described herein are methods for delivering an anti-cancer agent to a tumor in a subject. The method involves administering to the subject (i) gold particles and (ii) at least one-anti-cancer agent directly or indirectly bonded to the macromolecule and/or unbound to the macromolecule; and exposing the tumor to light for a sufficient time and wavelength in order for the gold particles to achieve surface plasmon resonance and heating the tumor.

Abstract: Materials and methods for magnetically guided delivery of nanoparticles across the blood brain barrier (BBB) in the central nervous system (CNS) are provided. The method can comprise injecting a subject with an aqueous solution comprising magneto-electro nanoparticles and applying a static magnetic field directed toward the subject brain, thereby inducing a stimulus response of the nanoparticles in a controlled manner. Materials and methods provided herein are effective in delivering the nanoparticles across the BBB in the brains of animal subjects including mice and non-human primate such as baboon.

Abstract: A method for making a modified release composition, comprising: selecting a desired active agent and polymer matrix for formulating into a modified release composition; assessing degradation effect on release of the active agent from the composition including plotting polymer molecular weight (Mwr) at onset of active agent release vs. active agent molecular weight (MwA); predicting performance of multiple potential formulations for the composition based on the degradation assessment and average polymer matrix initial molecular weight (Mwo) to define a library of building blocks; determining the optimal ratio of the building blocks to satisfy a specified release profile; and making a modified release composition based on the optimal ratio determination.

Abstract: This pharmaceutical composition contains a hydroxamic acid derivative, or a salt thereof, and a solubilizer, said hydroxamic acid derivative being selected from among (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, (2S)-2-((4-((4-((1R)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, and (2S)—N-hydroxy-2-((4-((4-((1S)-1-hydroxy-2-methoxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N?,2-dimethylmalonamide. The pharmaceutical composition demonstrates strong antibacterial activity, has excellent solubility in water, and is useful as a drug.

Abstract: An antibody-drug conjugate having a cyclic benzylidene acetal linker represented by formula (1) or formula (2), wherein Y is an antibody; D is a drug; R1 and R6 are each independently a hydrogen atom or a hydrocarbon group; R2, R3, R4 and R5 are each independently an electron-withdrawing or electron-donating substituent or a hydrogen atom; s is 1 or 2, t is 0 or 1, and s+t is 1 or 2; w is an integer of 1 to 20; and Z1 and Z2 are each independently a selected divalent spacer:

Abstract: The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.

Abstract: The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising at least one conjugate, wherein each conjugate includes a polyethylene glycol (PEG) polymer. Each conjugate also includes at least two amphiphilic compounds having both a hydrophilic face and a hydrophobic face. In addition, each conjugate includes an oligomer, wherein at least 2 of the amphiphilic compounds are covalently attached to the oligomer which is covalently attached to the PEG. The nanocarrier is such that each conjugate self-assembles in an aqueous solvent to form the nanocarrier such that a hydrophobic pocket is formed in the interior of the nanocarrier by the orientation of the hydrophobic face of each amphiphilic compound towards each other, and wherein the PEG of each conjugate self-assembles on the exterior of the nanocarrier.

Abstract: Polypeptides, such as a multi-valent polypeptide designated svD2, useful in pharmaceutical compositions for stimulation of the adaptive arm of the immune system. svD2 demonstrated in vivo activity in a syngeneic mouse model. svD2 is biologically active at nanomolar concentrations. These properties are believed to result as a consequence of the ability of svD2 to cross-link cell-surface receptors.

Abstract: The present invention discloses anti-PD-L/PD-1 Axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor/cancer.

Abstract: A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of: wherein: (a) R10 is H, and R11 is OH, ORA, where RA is saturated C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.

Abstract: The invention relates to a conjugate of a protein or peptide with a therapeutic, diagnostic or labelling agent, said conjugate containing a protein or peptide bonding portion and a polyethylene glycol portion; in which said protein or peptide bonding portion has the general formula: in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W? represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which said polyethylene glycol portion is or includes a pendant polyethylene glycol chain which has a terminal end group of formula —CH2CH2OR in which R represents a hydrogen atom, an alkyl group, or an optionally substituted aryl group. Also claimed are a method for making such a conjugate, and novel reagents useful in that method.

Abstract: The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors. The invention also relates to pharmaceutical compositions comprising said vectors.

Abstract: The present invention relates to compositions for and methods of optically imaging tissues or cells using imaging agents having desirable in vivo properties that result in improved signal-to-background ratio.

Abstract: The present invention relates to a method for detecting renal disease and for assessing the efficacy of dialysis treatment using imaging agents having desirable in vivo properties.

Abstract: Accordingly, certain embodiments of the invention provide a conjugate of formula (I): P-(X-D)n, wherein P is a peptide that binds to a glucose regulated protein 78 (GRP78); X is a direct bond or a linking group; D is a detectable agent; and n is 1 to 4. Certain embodiments of the invention provide a pharmaceutical composition comprising a conjugate of formula (I) and a pharmaceutically acceptable excipient. Certain embodiments of the invention provide a method for treating or preventing cancer in an animal (e.g., a human) comprising administering a therapeutically effective amount of a conjugate of formula (I) (e.g., a conjugate comprising a therapeutic radionuclide) to the animal.

Abstract: The presently disclosed subject matter provides compositions and kits comprising light-emitting versions of the monoclonal antibody to C3d (mAB 3d29) for imaging and methods of use thereof for detecting infectious and inflammatory cells in vivo. The presently disclosed subject matter also provides methods for detecting and/or monitoring a Mycobacterium tuberculosis (M. tuberculosis) infection in a subject, as well as methods of treating a M. tuberculosis infection in a subject.

Abstract: The invention provides cardiovascular imaging agents comprising an anticoagulant (e.g., dabigatran derivatives) with a label (e.g., radiolabeled, fluorinated or radiofluorinated). Methods for using the cardiovascular imaging agents and kits containing the cardiovascular imaging agents or components suitable for production of the cardiovascular imaging agents are also provided.

Abstract: A sterilizing apparatus having both excellent safety and operability is provided. A sterilizing apparatus (1) according to an aspect for carrying out the present invention is a sterilizing apparatus (1) that radiates light including ultraviolet rays onto an affected area (6), wherein first wavelength light (L?1) having a peak wavelength in a wavelength range of 190 nm or more and 230 nm or less, and second wavelength light (L?2) having a peak wavelength in a wavelength range of 400 nm or more and 780 nm or less are emitted.

Abstract: Embodiments of the invention include an ultraviolet (UV) source, the UV source including a semiconductor device comprising an active layer disposed between an n-type region and a p-type region. The active layer emits radiation having a peak wavelength in a UV range. A reflector cup is disposed around the UV source. A transparent cover is disposed over the reflector cup.

Abstract: A diffusive ultraviolet illuminator is provided. The illuminator can include a reflective mirror and a set of ultraviolet radiation sources located within a proximity of the focus point of the reflective mirror. The ultraviolet radiation from the set of ultraviolet radiation sources is directed towards a reflective surface located adjacent to the illuminator. The reflective surface can diffusively reflect at least 30% the ultraviolet radiation and the diffusive ultraviolet radiation can be within at least 40% of Lambertian distribution. A set of optical elements can be located between the illuminator and the reflective surface in order to direct the ultraviolet radiation towards at least 50% of the reflective surface.

Abstract: Embodiments of the present invention provide systems and methods for disinfection of aircraft galleys and lavatories and other surfaces. The embodiments may use UV light sources and/or a disinfection unit powered by a fuel cell or other external power source.

Abstract: Apparatuses having an ultraviolet light lamp are disclosed, where ultraviolet light is projected exterior to the apparatus and, in some embodiments, to a region 2-4 feet from a floor of a room in which the apparatus is arranged. In some cases, an apparatus includes a mobile carriage supporting the lamp and the apparatus is configured such that the lamp is not moveable beyond vertical planes aligned with a casing of the mobile carriage. Additional or alternative embodiments of apparatuses include a housing transparent to ultraviolet light surrounding the lamp and an exhaust duct extending from a gas outlet of the housing into a support structure that has an outlet disposed along its lower half portion or its bottom surface. Other embodiments of apparatuses include a pulsed ultraviolet light lamp and a sensor system to monitor and determine when to replace the pulsed lamp based on pulse count.

Abstract: An ultraviolet (UV) footwear illuminator for footwear treatment is disclosed. In one embodiment, the UV footwear illuminator includes an insert adapted for placement in an article of footwear. At least one UV radiation source is located in the insert and is configured to emit UV radiation in the footwear through a transparent window region formed in the insert. A control unit is configured to control at least one predetermined UV radiation characteristics associated with the radiation emitted from each UV radiation source. A power supply is configured to power each UV radiation source and the control unit.

Abstract: To simplify management of a process of sterilization of a filling nozzle. In a method for sterilizing a filling nozzle, hot water or a liquid chemical agent is fed to drink supply piping (7) that feeds a drink to a plurality of filling nozzles (2a) at the same time, the hot water or liquid chemical agent is discharged from all the filling nozzles (2a), a flow rate of the hot water or liquid chemical agent is detected at all the filling nozzles (2a), a representative temperature of the hot water or liquid chemical agent upstream or downstream of at least one filling nozzle is measured, and a sterilization process is ended when both the flow rate at each filling nozzle and the representative temperature reach respective target values.

Abstract: Device for discharging loose products includes a conveyor body attachable with its first end to a treatment machine for the loose products. The conveyor body, in correspondence to its second end, comprises a wall in which a collection aperture is made, selectively openable/closable by means of an opening/closing member to allow the discharge of said loose products. The discharge device for loose products further includes a pneumatic deliverer located in the conveyor body and configured to deliver a stream of gas at least toward the wall and determine the discharge, through the collection aperture, at least of the loose products that are deposited on the wall.

Abstract: A scent dispensing device comprising a porous material saturated with a scent composition and dried, such that the scent composition dispenses from the porous material when air flow is induced to pass through. The porous material comprises a dispense and a mount surface. The dispense surface is covered by a cover portion minimizing contact with the scent composition. A base portion joins the mount surface. An adhesive portion on the mount surface helps adhere the porous material to an air flow inducing object that induces air flow through the porous material, dispersing the scent composition in the proximity of a path followed by the air flow inducing object. The porosity of the porous material creates turbulence that releases the scent. A panel portion covers the adhesive portion until device is ready for mounting. A tab portion provides a gripping surface for removing the panel portion.

Abstract: The invention relates to packaged deodorizing products, and in particular, packaged deodorizing products that find use in toileting. In some aspects, the packaged deodorizing product includes a solid substrate such as rice paper, gelatin sheets, or any other suitable substrate, that disintegrates when exposed to water such as in a toilet bowl, where the solid substrate has been pre-infused with a scenting agent, for example, an essential oil. The deodorizing product is removed from the packaging and placed directly into a toilet bowl prior to toileting, thereby expediting the action of the scenting agent. After toileting, the scenting agent is substantially removed when the toilet is flushed. The invention can also be used as a deodorizing product without deployment in liquid water.

Abstract: A device comprises a delivery engine comprising a volatile composition and a microporous membrane, and an evaporation assistance element. In some embodiments the device includes a fan is configured to move a volume of air over the microporous membrane to facilitate evaporation of the volatile composition into the atmosphere.

Abstract: A system for disinfecting a fluid, including: a flow cell including one or more inlet ports and one or more outlet ports, wherein the flow cell is configured to communicate a fluid containing a biological contaminant from the one or more inlet ports to the one or more outlet portions through an interior portion thereof; and one or more point radiation sources disposed about the flow cell, wherein the one or more point radiation sources are operable for delivering radiation to the biological contaminant; wherein an interior surface of the flow cell is operable for reflecting the radiation delivered to the biological contaminant by the one or more point radiation sources; and wherein the interior surface of the flow cell is operable for reflecting the radiation delivered to the biological contaminant by the one or more point radiation sources such that a radiation intensity is uniform throughout the interior portion of the flow cell. In one exemplary embodiment, the flow cell is an integrating sphere.

Abstract: The present invention provides compositions and methods that promote wound healing in a subject with a cutaneous injury. In particular, the present invention provides systemic and/or local administration of one or more compositions that cause ganglioside depletion (e.g., glucosylceramide synthase (GCS) inhibitors) for the treatment of cutaneous wounds.

Abstract: The invention includes a hot melt adhesive composition based on polyolefin polymers that can be used for construction applications in a disposable absorbent article. The olefin based hot melt adhesive composition has surprisingly good cohesive strength and a low odor.

Abstract: A soft film, a sponge, or a sheet in the dried state is provided, which is capable of forming a hydrogel absorbing water or blood. The film is obtainable by preparing a film-state material in the dried state from either a solution of poly(acrylic acid) or a solution of polyvinylpyrrolidone, and bringing the film-state material into contact with the other remaining solution, and then drying or freeze-drying it.

Abstract: Disclosed are micronized hydrophilic systems of highly concentrated, cross-linked biopolymers. The system is created by combining a biopolymer with a cross-linking agent under mechanical kneading and allowing the biopolymer to undergo a cross-linking process followed by purification, drying and milling. The resulting micronized biopolymer system has an increased biopolymer concentration and increased longevity within the body.

Abstract: Once aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compsitions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound.

Abstract: Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).

Abstract: Wound repair materials and methods of using the same to inhibit excess fibrosis are disclosed.

Abstract: A mixture for an injectable scaffold may include a self-assembling core and an additive. The additive may include an angiogenic agent, a small molecule drug, and/or an anti-inflammatory agent. The scaffold can be applied to sites where bone growth is desired.

Abstract: An implant for bone-graft insertedly placed in a procedure pore, the implant includes a bone organism having a lump shape, and a protective film coated to cover an overall outer surface of the bone organism as to form an absorbent membrane. After the implant is insertedly placed in the procedure pore, the absorbent member is absorbed into a body and dissolved as time passes. The implant for the bone-graft may be applied to diverse procedures performed for hone-graft not only in a dental surgery but also in orthopedics or a plastic surgery.

Abstract: The present invention relates to a tissue-engineered intervertebral disc (IVD) suitable for total disc replacement in a mammal and methods of fabrication. The IVD comprises a nucleus pulposus structure comprising a first population of living cells that secrete a hydrophilic protein and an annulus fibrosis structure surrounding and in contact with the nucleus pulposus structure, the annulus fibrosis structure comprising a second population of living cells and type I collagen. The collagen fibrils in the annulus fibrosis structure are circumferentially aligned around the nucleus pulposus region due to cell-mediated contraction in the annulus fibrosis structure. Also disclosed are methods of fabricating tissue-engineered intervertebral discs.

Abstract: The present invention provides a method for treating spinal cord injury and repairing or regenerating a damaged spinal cord tissue comprising administering a composition comprising a sulfated alginate or sulfated hyaluronan optionally affinity-bound to one or more growth factors.

Abstract: A medical device for insertion or implantation in a body includes a polymer substrate and a layer of poly(vinyl pyrrolidone-alt-maleic anhydride) formed on a surface of the polymer substrate. Polymer chains of the poly(vinyl pyrrolidone-alt-maleic anhydride) are entangled with the polymer substrate.

Abstract: The present invention relates to a method for preparing a chitosan matrix having good mechanical properties comprising the steps of a) preparing a solution of chitosan, b) pouring the solution of a) into a mould in order to form a layer, c) lyophilizing the layer of b) in order to obtain a matrix of chitosan, d) sterilizing the matrix obtained in c) by water vapor treatment. The invention also relates to the matrices obtained and to surgical implants comprising such matrices. The invention further relates to a method for increasing the suture retention strength of a chitosan matrix obtained by lyophilization of a chitosan solution, and to a method for for decreasing the solubilization rate in hydrochloric acid of a chitosan matrix obtained by lyophilization of a chitosan solution, comprising the step of sterilizing said matrix by a water vapor treatment.

Abstract: A method of making a solution including poly(ethylene terephthalate). The method includes dissolving poly(ethylene terephthalate) in a solvent mixture to form a solution, the solvent mixture including two solvent components. A Hansen Solubility Parameter Distance between the solvent mixture and HSP coordinates having a dispersion HSP of 18.02 MPa0.5, a polar HSP of 5.56 MPa0.5, and a hydrogen bonding HSP of 14.27 MPa0.5 is less than about 2 MPa0.5.